This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
HOLX Stock Down 24.7% in 6 Months: Time to Cut Losses or Buy the Dip?
by Moumi Mondal
As Hologic works through the changing macroeconomic and geopolitical landscape, its long-term potential makes it a solid hold.
Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Abbott (ABT) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
by Zacks Equity Research
Sector ETF report for RSPH
Abbott Laboratories Gains 12.7% in a Year: What's Driving the Stock?
by Zacks Equity Research
ABT's shares rise on the back of its diversified business portfolio. However, the unfavorable macroeconomic scenario is concerning.
QuidelOrtho Unveils Results Manager System to Streamline Testing
by Zacks Equity Research
QDEL introduces the Results Manager System, a powerful tool designed to streamline diagnostic data management, enhance efficiency, and improve patient care.
DexCom CGM Sensor Sales to Continue Despite FDA Warning Letter
by Zacks Equity Research
DXCM faces an FDA warning over manufacturing issues, but operations remain unaffected. However, supply-chain risks and rising competition pose challenges.
Abbott (ABT) Stock Moves -0.3%: What You Should Know
by Zacks Equity Research
Abbott (ABT) reachead $129.89 at the closing of the latest trading day, reflecting a -0.3% change compared to its last close.
Hims & Hers Stock Gains 8.6% in Three Months: How to Play It?
by Debanjana Dey
HIMS is enhancing offerings and expanding its health and wellness products and services to solidify its footing. However, macro challenges are likely to hurt its performance.
Abbott (ABT) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $130.28, moving -1.79% from the previous trading session.
EPD Expansion Supports Abbot Stock, Macro Issues Prevail
by Zacks Equity Research
ABT's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
Why Is Envista (NVST) Down 18.2% Since Last Earnings Report?
by Zacks Equity Research
Envista (NVST) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Abbott (ABT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Abbott (ABT) stood at $137.71, denoting a +0.09% change from the preceding trading day.
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
AHCO vs. ABT: Which Stock Is the Better Value Option?
by Zacks Equity Research
AHCO vs. ABT: Which Stock Is the Better Value Option?
Is American Century U.S. Quality Value ETF (VALQ) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for VALQ
Abbott (ABT) Stock Moves -0.07%: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $135.87, marking a -0.07% move from the previous day.
Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Abbott (ABT) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
BWAY Drops 15% in Four Days: How to Play the Stock Before Earnings?
by Harshit Gupta
BWAY stock continues to struggle near its IPO price despite growth. With rising revenues, global expansion and valuation concerns, is it a buy, hold or sell before earnings?
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Distributor Purchasing Shifts Mar MDT's Q3 Show: How to Play the Stock
by Urmimala Biswas
Medtronic's Medical Surgical segment faces challenges in the third quarter due to shifts in U.S. distributor buying patterns.
Abbott (ABT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $134.92, moving +1.31% from the previous trading session.
4 Seniors & Aging Demographics Stocks to Watch Right Now
by Urmimala Biswas
ABBV, AMGN, SYK and DXCM are well-poised to benefit from the evolving new opportunities in Seniors & Aging Demographics within healthcare.
Abbott (ABT) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
The latest trading day saw Abbott (ABT) settling at $133.17, representing a +0.79% change from its previous close.
Boston Scientific Expects Strong Gains in 2025: Time to Buy the Stock?
by Urmimala Biswas
Boston Scientific begins 2025 on a solid note, expecting organic revenue growth of 14% to 16% in the first quarter.